532 related articles for article (PubMed ID: 30940648)
1. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
[TBL] [Abstract][Full Text] [Related]
2. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
Zhang L; Li DQ
Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
[TBL] [Abstract][Full Text] [Related]
3. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
Wang Y; Wang Y; Wang N; You L; Long F; Shao C; Wang Y; Wu J
Oncol Rep; 2019 Oct; 42(4):1467-1474. PubMed ID: 31322269
[TBL] [Abstract][Full Text] [Related]
5. Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.
Frankum J; Moudry P; Brough R; Hodny Z; Ashworth A; Bartek J; Lord CJ
Oncotarget; 2015 May; 6(13):10746-58. PubMed ID: 25883215
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs.
Valdez BC; Nieto Y; Yuan B; Murray D; Andersson BS
Oncotarget; 2022 Oct; 13():1122-1135. PubMed ID: 36243940
[TBL] [Abstract][Full Text] [Related]
7. Poly-ADP ribosylation in DNA damage response and cancer therapy.
Hou WH; Chen SH; Yu X
Mutat Res Rev Mutat Res; 2019; 780():82-91. PubMed ID: 31395352
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins.
Alemasova EE; Lavrik OI
Nucleic Acids Res; 2019 May; 47(8):3811-3827. PubMed ID: 30799503
[TBL] [Abstract][Full Text] [Related]
9. Nuclear PTEN interferes with binding of Ku70 at double-strand breaks through post-translational poly(ADP-ribosyl)ation.
Guan J; Zhao Q; Mao W
Biochim Biophys Acta; 2016 Dec; 1863(12):3106-3115. PubMed ID: 27741411
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
11. CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells.
Wu W; Zhao J; Xiao J; Wu W; Xie L; Xie X; Yang C; Yin D; Hu K
Biochem Biophys Res Commun; 2021 Oct; 573():62-68. PubMed ID: 34388456
[TBL] [Abstract][Full Text] [Related]
12. [Poly(ADP-Ribose) Polymerases 1 and 2: Classical Functions and Interaction with New Histone Poly(ADP-Ribosyl)ation Factor HPF1].
Kurgina TA; Lavrik OI
Mol Biol (Mosk); 2023; 57(2):254-268. PubMed ID: 37000654
[TBL] [Abstract][Full Text] [Related]
13. [PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective].
Wiśnik E; Ryksa M; Koter-Michalak M
Postepy Hig Med Dosw (Online); 2016 Apr; 70():280-94. PubMed ID: 27117104
[TBL] [Abstract][Full Text] [Related]
14. PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1.
Liu L; Kong M; Gassman NR; Freudenthal BD; Prasad R; Zhen S; Watkins SC; Wilson SH; Van Houten B
Nucleic Acids Res; 2017 Dec; 45(22):12834-12847. PubMed ID: 29121337
[TBL] [Abstract][Full Text] [Related]
15. Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities.
Khadka P; Hsu JK; Veith S; Tadokoro T; Shamanna RA; Mangerich A; Croteau DL; Bohr VA
Mol Cell Biol; 2015 Dec; 35(23):3974-89. PubMed ID: 26391948
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribosyl)ation links the chromatin remodeler SMARCA5/SNF2H to RNF168-dependent DNA damage signaling.
Smeenk G; Wiegant WW; Marteijn JA; Luijsterburg MS; Sroczynski N; Costelloe T; Romeijn RJ; Pastink A; Mailand N; Vermeulen W; van Attikum H
J Cell Sci; 2013 Feb; 126(Pt 4):889-903. PubMed ID: 23264744
[TBL] [Abstract][Full Text] [Related]
17. PARP1 is activated by membrane damage and is involved in membrane repair through poly(ADP-ribosyl)ation.
Mashimo M; Kita M; Nobeyama A; Nomura A; Fujii T
Genes Cells; 2022 Apr; 27(4):305-312. PubMed ID: 35124853
[TBL] [Abstract][Full Text] [Related]
18. Selective targeting of ubiquitination and degradation of PARP1 by E3 ubiquitin ligase WWP2 regulates isoproterenol-induced cardiac remodeling.
Zhang N; Zhang Y; Qian H; Wu S; Cao L; Sun Y
Cell Death Differ; 2020 Sep; 27(9):2605-2619. PubMed ID: 32139900
[TBL] [Abstract][Full Text] [Related]
19. Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage.
Kang HC; Lee YI; Shin JH; Andrabi SA; Chi Z; Gagné JP; Lee Y; Ko HS; Lee BD; Poirier GG; Dawson VL; Dawson TM
Proc Natl Acad Sci U S A; 2011 Aug; 108(34):14103-8. PubMed ID: 21825151
[TBL] [Abstract][Full Text] [Related]
20. Deltex family E3 ligases specifically ubiquitinate the terminal ADP-ribose of poly(ADP-ribosyl)ation.
Kelly M; Dietz C; Kasson S; Zhang Y; Holtzman MJ; Kim IK
Biochem Biophys Res Commun; 2024 Aug; 720():150101. PubMed ID: 38749191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
